NCT01485406View on ClinicalTrials.gov

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

December 12, 2011

Primary Completion Date

March 15, 2012

Study Completion Date

March 15, 2012

Conditions
Infections, Streptococcal
Interventions
BIOLOGICAL

Pneumococcal vaccine GSK2830930A

1 dose administered intramuscularly

BIOLOGICAL

Synflorix™

1 dose administered intramuscularly

Trial Locations (4)

13055

GSK Investigational Site, Berlin

34225

GSK Investigational Site, Braunatal

77694

GSK Investigational Site, Kehl

83471

GSK Investigational Site, Berchtesgaden

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01485406 - Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers | Biotech Hunter | Biotech Hunter